Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition.

January 15, 2016 By:
  • Herkert B
  • Kauffmann A
  • Molle S
  • Schnell C
  • Ferrat T
  • Voshol H
  • Juengert J
  • Erasimus H
  • Marszalek G
  • Kazic-Legueux M
  • Billy E
  • Ruddy D
  • Stump M
  • Guthy D
  • Ristov M
  • Calkins K
  • Maira SM
  • Sellers WR
  • Hofmann F
  • Hall MN
  • Brachmann SM.

The introduction of MAPK pathway inhibitors paved the road for significant advancements in the treatment of BRAF-mutant (BRAF(MUT)) melanoma. However, even BRAF/MEK inhibitor combination therapy has failed to offer a curative treatment option, most likely because these pathways constitute a codependent signaling network. Concomitant PTEN loss of function (PTEN(LOF)) occurs in approximately 40% of BRAF(MUT) melanomas. In this study, we sought to identify the nodes of the PTEN/PI3K pathway that would be amenable to combined therapy with MAPK pathway inhibitors for the treatment of PTEN(LOF)/BRAF(MUT) melanoma. Large-scale compound sensitivity profiling revealed that PTEN(LOF) melanoma cell lines were sensitive to PI3Kbeta inhibitors, albeit only partially. An unbiased shRNA screen (7,500 genes and 20 shRNAs/genes) across 11 cell lines in the presence of a PI3Kbeta inhibitor identified an adaptive response involving the IGF1R-PI3Kalpha axis. Combined inhibition of the MAPK pathway, PI3Kbeta, and PI3Kalpha or insulin-like growth factor receptor 1 (IGF1R) synergistically sustained pathway blockade, induced apoptosis, and inhibited tumor growth in PTEN(LOF)/BRAF(MUT) melanoma models. Notably, combined treatment with the IGF1R inhibitor, but not the PI3Kalpha inhibitor, failed to elevate glucose or insulin signaling. Taken together, our findings provide a strong rationale for testing combinations of panPI3K, PI3Kbeta + IGF1R, and MAPK pathway inhibitors in PTEN(LOF)/BRAF(MUT) melanoma patients to achieve maximal response.

2016 Jan. Cancer Res.76(2):390-402. Epub 2015 Nov 17.
Other information